Compare AstraZeneca plc (AZN) vs Honeywell International Inc (HON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Honeywell International Inc — how do they compare? AstraZeneca plc trades at $166.73 (market cap $253.13B), while Honeywell International Inc trades at $222.7 (market cap $70.55B). The key difference: AstraZeneca plc is far larger — about 3.6× Honeywell International Inc's market cap, and Honeywell International Inc pays the higher dividend (4.28%). Which is the better fit depends on your goals.
| AZN | HON | |
|---|---|---|
Market Cap | $253.13B | $70.55B |
Sector | Health | Industrials |
52-Week High | $209.48 | $248.04 |
52-Week Low | $137.44 | $188.14 |
Enterprise Value | $279.37B | $94.90B |
Dividend Yield | 1.92% | 4.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
Honeywell (HON) trades at $222.25, down 1.84% on the day, with a bearish technical signal. The company reported strong recent earnings beats but faces near-term uncertainty from its Aerospace and Quantinuum spinoffs. Key financials show solid profitability with a 10.89% net margin and 26.41% ROE, though revenue declined slightly in 2025. A recent 2:1 reverse stock split and updated 2026 guidance aim to streamline operations. Analyst consensus remains strongly bullish with a $368.55 price target, but technical indicators suggest caution.
The outlook for HON hinges on successful execution post-spinoff and margin improvement targets. Investment opportunity lies in its focused automation and industrial technology portfolio, attractive valuation (P/E 17.75), and strong analyst support. Key risks include near-term earnings volatility, competitive pressures, and macroeconomic headwinds impacting industrial demand. The stock's current bearish technical trend warrants monitoring for stabilization above key support levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Honeywell International Inc
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →
